- Published on
Ophthalmology – Central Serous Chorioretinopathy (CSCR)
Central serous chorioretinopathy (CSCR) is a retinal disorder characterized by accumulation of fluid under the neurosensory retina, most commonly affecting the macula. This results from leakage of fluid through defects in the retinal pigment epithelium (RPE), often associated with small pigment epithelial detachments. The condition typically presents with a localized serous retinal detachment, and in rare cases, a more extensive “bullous” variant may occur with large shifting subretinal fluid. CSCR primarily affects otherwise healthy adults and is usually limited to the eye without systemic ocular involvement.
Epidemiologically, CSCR occurs predominantly in men between 25 and 50 years of age, with a strong male predominance (approximately 6:1). It is relatively uncommon but not rare, and recurrence occurs in about 30% of patients, sometimes years after the initial episode. Risk factors include corticosteroid use (in any form), psychological stress, and so-called “type A” personality traits. Conditions associated with elevated endogenous corticosteroids, such as Cushing’s disease, are also linked to CSCR.
The underlying pathophysiology involves dysfunction of the retinal pigment epithelium, allowing fluid from the choroid to pass into the subretinal space. Although the exact mechanism remains unclear, corticosteroids are believed to alter choroidal circulation and RPE permeability. The result is a serous detachment of the sensory retina, often centered at the macula, which leads to visual symptoms.
Patients typically present with blurred central vision, often described as a gray or dark spot (central scotoma). Visual distortion (metamorphopsia) and perception of objects appearing smaller than normal (micropsia) are common. Some patients report a history of recent emotional stress or corticosteroid exposure. On examination, a well-defined serous detachment of the macula is seen, sometimes with subretinal deposits. Importantly, the absence of hemorrhage helps distinguish CSCR from conditions like neovascular age-related macular degeneration.
Diagnosis is confirmed with imaging. Fluorescein angiography reveals focal leakage at the level of the RPE, often demonstrating a characteristic “smokestack” or “inkblot” pattern of dye diffusion. Optical coherence tomography (OCT) is especially useful, showing a dome-shaped elevation of the neurosensory retina with underlying RPE detachment. These imaging modalities are essential both for diagnosis and monitoring.
Management is often conservative, as approximately 85% of cases resolve spontaneously within 3–4 months with reabsorption of subretinal fluid. Observation is therefore the first-line approach in most patients. If the condition persists beyond several months or significantly affects vision, treatment options include focal laser photocoagulation to seal leakage sites or photodynamic therapy (especially when leakage is close to the fovea). Intravitreal anti-VEGF therapy, such as bevacizumab, has shown some benefit in selected cases.
The prognosis for CSCR is generally favorable, with over 90% of patients recovering visual acuity of 20/30 or better within 6 months. However, recurrent or chronic cases may lead to persistent RPE changes, subretinal fluid, and gradual visual decline. Long-term complications can include reduced visual acuity and, rarely, development of choroidal neovascularization. Regular follow-up is important, particularly in patients with recurrent disease or ongoing risk factors.
Central serous chorioretinopathy (CSCR) is a retinal disorder characterized by accumulation of fluid under the neurosensory retina, most commonly affecting the macula. This results from leakage of fluid through defects in the retinal pigment epithelium (RPE), often associated with small pigment epithelial detachments. The condition typically presents with a localized serous retinal detachment, and in rare cases, a more extensive “bullous” variant may occur with large shifting subretinal fluid. CSCR primarily affects otherwise healthy adults and is usually limited to the eye without systemic ocular involvement.
Epidemiologically, CSCR occurs predominantly in men between 25 and 50 years of age, with a strong male predominance (approximately 6:1). It is relatively uncommon but not rare, and recurrence occurs in about 30% of patients, sometimes years after the initial episode. Risk factors include corticosteroid use (in any form), psychological stress, and so-called “type A” personality traits. Conditions associated with elevated endogenous corticosteroids, such as Cushing’s disease, are also linked to CSCR.
The underlying pathophysiology involves dysfunction of the retinal pigment epithelium, allowing fluid from the choroid to pass into the subretinal space. Although the exact mechanism remains unclear, corticosteroids are believed to alter choroidal circulation and RPE permeability. The result is a serous detachment of the sensory retina, often centered at the macula, which leads to visual symptoms.
Patients typically present with blurred central vision, often described as a gray or dark spot (central scotoma). Visual distortion (metamorphopsia) and perception of objects appearing smaller than normal (micropsia) are common. Some patients report a history of recent emotional stress or corticosteroid exposure. On examination, a well-defined serous detachment of the macula is seen, sometimes with subretinal deposits. Importantly, the absence of hemorrhage helps distinguish CSCR from conditions like neovascular age-related macular degeneration.
Diagnosis is confirmed with imaging. Fluorescein angiography reveals focal leakage at the level of the RPE, often demonstrating a characteristic “smokestack” or “inkblot” pattern of dye diffusion. Optical coherence tomography (OCT) is especially useful, showing a dome-shaped elevation of the neurosensory retina with underlying RPE detachment. These imaging modalities are essential both for diagnosis and monitoring.
Management is often conservative, as approximately 85% of cases resolve spontaneously within 3–4 months with reabsorption of subretinal fluid. Observation is therefore the first-line approach in most patients. If the condition persists beyond several months or significantly affects vision, treatment options include focal laser photocoagulation to seal leakage sites or photodynamic therapy (especially when leakage is close to the fovea). Intravitreal anti-VEGF therapy, such as bevacizumab, has shown some benefit in selected cases.
The prognosis for CSCR is generally favorable, with over 90% of patients recovering visual acuity of 20/30 or better within 6 months. However, recurrent or chronic cases may lead to persistent RPE changes, subretinal fluid, and gradual visual decline. Long-term complications can include reduced visual acuity and, rarely, development of choroidal neovascularization. Regular follow-up is important, particularly in patients with recurrent disease or ongoing risk factors.
0 Comments
